Guggenheim Upgrades Eloxx Pharmaceuticals (NASDAQ:ELOX) to “Strong-Buy”

Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) was upgraded by analysts at Guggenheim to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Eloxx Pharmaceuticals Price Performance

NASDAQ ELOX opened at $11.65 on Monday. Eloxx Pharmaceuticals has a 1-year low of $11.61 and a 1-year high of $17.50. The firm has a market capitalization of $8.02 million, a P/E ratio of -0.76 and a beta of -1,891.27. The stock has a fifty day moving average of $17.35.

Get Eloxx Pharmaceuticals alerts:

About Eloxx Pharmaceuticals

(Get Free Report)

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.

Recommended Stories

• Five stocks we like better than Eloxx Pharmaceuticals
• The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
• Is Domino’s Stock Serving Up a Buying Opportunity?
• A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
• Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.